Ispecimen Stock Today
| ISPC Stock | USD 1.34 0.07 5.51% |
PerformanceVery Weak
| Odds Of DistressVery High
|
ISpecimen is trading at 1.34 as of the 16th of March 2025, a 5.51 percent increase since the beginning of the trading day. The stock's open price was 1.27. ISpecimen has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of June 2021 | Category Healthcare | Classification Health Care |
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts. The company has 962.64 K outstanding shares of which 29.56 K shares are currently shorted by private and institutional investors with about 0.1 trading days to cover. More on iSpecimen
Moving together with ISpecimen Stock
| 0.64 | VRCA | Verrica Pharmaceuticals | PairCorr |
| 0.78 | ENVB | Enveric Biosciences Earnings Call Next Week | PairCorr |
Moving against ISpecimen Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ISpecimen Stock Highlights
| Treasurer, CEO | Robert Lim | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Ispac 1 Ltd | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsISpecimen can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ISpecimen's financial leverage. It provides some insight into what part of ISpecimen's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
iSpecimen (ISPC) is traded on NASDAQ Exchange in USA. It is located in 450 Bedford Street, Lexington, MA, United States, 02420 and employs 53 people. ISpecimen is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.29 M. iSpecimen conducts business under Biotechnology sector and is part of Health Care industry. The entity has 962.64 K outstanding shares of which 29.56 K shares are currently shorted by private and institutional investors with about 0.1 trading days to cover.
iSpecimen currently holds about 23.69 M in cash with (5.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check ISpecimen Probability Of Bankruptcy
Ownership AllocationISpecimen retains 14.5 (percent) of its outstanding shares held by insiders and 3.71 (percent) owned by outside corporations.
Check ISpecimen Ownership Details
ISpecimen Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Fny Investment Advisers, Llc | 2024-12-31 | 0.0 | |
| Vanguard Group Inc | 2024-09-30 | 0.0 | |
| Geode Capital Management, Llc | 2024-09-30 | 0.0 | |
| Main Street Financial Solutions, Llc (pa) | 2024-09-30 | 0.0 | |
| Virtu Financial Llc | 2024-09-30 | 0.0 | |
| Hrt Financial Llc | 2024-09-30 | 0.0 | |
| Bridgeway Capital Management, Llc | 2024-12-31 | 21.8 K | |
| Ubs Group Ag | 2024-12-31 | 11 K | |
| Blackrock Inc | 2024-12-31 | 2.8 K | |
| Tower Research Capital Llc | 2024-12-31 | 131 | |
| Bank Of America Corp | 2024-12-31 | 7.0 |
ISpecimen Historical Income Statement
ISpecimen Stock Against Markets
ISpecimen Corporate Management
| Emily Hubbard | VP Devel | Profile | |
| Benjamin Bielak | Chief Secretary | Profile | |
| Eric Langlois | Chief Officer | Profile | |
| Dawn Michelle | VP Operations | Profile | |
| Yuying Liang | Chief Officer | Profile | |
| Annette Arnold | Vice Development | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iSpecimen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ISpecimen. If investors know ISpecimen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ISpecimen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (18.12) | Revenue Per Share | Quarterly Revenue Growth (0.04) | Return On Assets | Return On Equity |
The market value of iSpecimen is measured differently than its book value, which is the value of ISpecimen that is recorded on the company's balance sheet. Investors also form their own opinion of ISpecimen's value that differs from its market value or its book value, called intrinsic value, which is ISpecimen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ISpecimen's market value can be influenced by many factors that don't directly affect ISpecimen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ISpecimen's value and its price as these two are different measures arrived at by different means. Investors typically determine if ISpecimen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ISpecimen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.